PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-24.66%
Cash & equivalents declining -24.66% while Medical - Pharmaceuticals shows -4.87% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-24.66%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -5.20%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
14.05%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.53%. Jim Chanos might see a serious red flag in ballooning receivables.
-0.11%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-1.93%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-8.94%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of -2.85%. Joel Greenblatt sees a potential liquidity edge if well allocated.
10.20%
PP&E growth below half of Medical - Pharmaceuticals median of -0.24%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
3.78%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
3.78%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
0.65%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-367.44%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
0.46%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.42%
≥ 1.5x the Medical - Pharmaceuticals median of 0.74%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
-0.78%
0.5-0.75x Medical - Pharmaceuticals median of -1.16%. Guy Spier is cautious about potential underinvestment relative to sector.
-1.77%
Payables growth below half of Medical - Pharmaceuticals median of 0.80%. Joel Greenblatt sees more conservative payables management vs. peers.
-5.03%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-59.17%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-58.10%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-0.66%
50-75% Medical - Pharmaceuticals median of -0.97%. Mohnish Pabrai notes a more conservative near-term liability profile.
-3.89%
Above 1.5x Medical - Pharmaceuticals median of -0.91%. Jim Chanos suspects potential working capital strain.
-8.82%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.22%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-2.68%
Above 1.5x Medical - Pharmaceuticals median of -0.16%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-3.81%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
2.11%
Below half Medical - Pharmaceuticals median of -1.57%. Jim Chanos suspects poor profitability or large dividend drains.
10.00%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
2.01%
Below half Medical - Pharmaceuticals median of -0.57%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-0.78%
0.5-0.75x Medical - Pharmaceuticals median of -1.16%. Guy Spier is cautious about underexpansion vs. peers.
0.65%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-7.70%
Above 1.5x Medical - Pharmaceuticals median of -0.60%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
26.89%
Above 1.5x Medical - Pharmaceuticals median 4.07%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.